Sandell Scott D's Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Jan 27, 2023
- Accession no.
- 0001209191-23-005326
- Filed
- Jan 27, 2023
- Trade date
- Jan 25-26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $11.5M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandell Scott DCIK 0001237289 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 25, 2023 | Common Stock | SSaleDisposed | −358,371 | $3.26 | −$1,168,289.46 | 4,379,242 | Indirect | |
| Jan 25, 2023 | Common Stock | SSaleDisposed | −293,645 | $3.26 | −$957,282.7 | 3,588,288 | Indirect | |
| Jan 26, 2023 | Common Stock | SSaleDisposed | −1,648,908 | $3.12 | −$5,144,592.96 | 2,730,334 | Indirect | |
| Jan 26, 2023 | Common Stock | SSaleDisposed | −1,351,092 | $3.12 | −$4,215,407.04 | 2,237,196 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.